Fidia Announces Expansion into the US Dietary Supplement Market with Launch of CartiJoint™ FORTE

Fidia Farmaceutici is introducing CartiJoint™ FORTE, its first product in the dietary supplement category in the USA, through its wholly-owned subsidiary based in the U.S., Fidia Pharma USA Inc.

CartiJoint™ FORTE is a dietary supplement that supports joint health and mobility with antioxidant activity in a daily dose. It is uniquely formulated with a bioactive curcumin extract Bio-Curcumin Curcugreen™ which is 100% natural turmeric along with glucosamine hydrochloride and chondroitin sulfate.

The introduction of CartiJoint™ FORTE reinforces Fidia’s growth in the U.S., by diversifying into new, emerging product categories that are in line with the company mission of innovating and pioneering new treatment options that will benefit patients, as well as healthcare providers.

Unique formulation with a bioactive curcumin extract Bio-Curcumin Curcugreen™ (100% natural turmeric), glucosamine hydrochloride and chondroitin sulfate.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine